Olaparib in ovarian cancer with BRCA mutation;Olaparib dans les cancers de l'ovaire avec mutation BRCA

Bulletin du Cancer

Volumn 102, Issue 6, 2015, Pages S82-S84

  Pujade Lauraine, Éric ^a   Combe, Pierre ^b  

^a HÔTEL DIEU   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

BRCA; Olaparib; Ovarian cancer; PARP

Indexed keywords

BRCA PROTEIN; OLAPARIB; PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

AGE; CANCER STAGING; GENE MUTATION; OVARY CANCER; REVIEW; ANTAGONISTS AND INHIBITORS; FEMALE; GENE SILENCING; GENETICS; HUMAN; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; FEMALE; GENE SILENCING; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84938082015     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1016/S0007-4551(15)31221-2     Document Type: Review

References (2)

1. Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, et al. Cancer de l'ovaire héréditaire : présentations clinico-biologiques et traitement. Bull Cancer 2014;101:167-74.
2. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61.